Whitehawk Therapeutics Inc (WHWK) Q4 2025 Earnings Call Transcript

Why It Matters

The moves boost earnings per share and narrow the persistent discount to NAV, enhancing shareholder value in a competitive BDC market.

Key Takeaways

• Net investment income increased to $6.6M, up 8% quarter‑over‑quarter
• NAV per share rose 2.4% to $11.68, aided by buybacks
• Board expanded share repurchase authorization by $7.5M, $15M remaining
• Incentive fee cut to 17.5% saved ~$200k in Q4
• First‑lien loan originations totaled $64M, maintaining high credit quality

Pulse Analysis

WhiteHorse Therapeutics’ fourth‑quarter results underscore how Business Development Companies (BDCs) can leverage share‑repurchase programs to address chronic price‑to‑book discounts. By buying back one million shares at roughly $7.4 million, the firm added 18.4 cents per share to NAV, a tangible accretion that investors monitor closely. Coupled with a modest dividend increase and a supplemental 1‑cent payout, the strategy signals a commitment to returning capital while preserving growth capital for future deployments. In a market where many BDCs trade below intrinsic value, such disciplined capital allocation can narrow spreads and attract income‑focused investors.

The quarter also highlighted strategic financing and cost‑management initiatives. The $164 million CLO issuance of AAA‑rated notes, priced at SOFR + 170 bps, diversified funding sources and reduced reliance on higher‑cost senior debt. Simultaneously, the adviser’s voluntary reduction of the incentive fee from 20% to 17.5% trimmed expenses by about $200 k, directly bolstering distributable earnings. For BDCs, fee structures and leverage costs are pivotal levers; lowering them improves net investment income, which in turn supports higher dividend yields—a key metric for the sector’s investor base.

Portfolio quality remains a cornerstone of WhiteHorse’s outlook. With 99.7% of the debt portfolio in first‑lien, senior‑secured positions and 85.9% rated in the top two tiers, the firm demonstrates resilience amid a tightening credit environment. Non‑accrual exposure stayed modest at 2.4%, and the firm continued active restructuring of distressed assets. Looking ahead, management anticipates a modest rebound in deal flow as interest rates stabilize, but acknowledges limited balance‑sheet capacity. By focusing on non‑sponsor transactions, where competition is softer and risk‑adjusted returns are higher, WhiteHorse aims to sustain earnings growth while navigating market volatility.